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Abstract
Bone density and bone microarchitecture are two principle parameters needed
for the evaluation of mechanical bone performance and consequently the detection
of bone diseases. The mechanobiological behavior of the skeletal tissue has been
described through several mathematical models. Generally, these models finger-
board different length scale processes, such as the mechanical, the biological, and
the chemical ones. By means of the mechanical stimulus and the biological factors
involved in tissue regeneration, bone cells’ behavior and bone volume changes are
determined. The emergence of bone diseases leads to disrupt the bone remodeling
process and thus, induces bone mechanical properties’ alteration. In the present
chapter, an overview of bone diseases and their relationship with bone density
alteration will be presented. Besides, several studies treating bone diseases’ effect on
bone remodeling will be discussed. Finally, the mechanobiological models proposed
to treat bone healing and drugs’ effect on bone, are going to be reviewed. For this
sake, the chapter is subdivided into three main sequences: (i) Bone remodeling, (ii)
Bone deterioration causes, (iii) Mathematical models of a pathological bone, and
(iv) Mechanobiological models treating bone healing and drugs effect.
Keywords: mechanobiological modeling, bone remodeling, mathematical models,
bone diseases, bone healing, drugs
1. Introduction
An adult body skeleton is renewed once each 10 years as a median frequency.
The renewing is the result of a biological process, persisting in the human body,
known as bone remodeling. This biological phenomenon has been defined, for the
first time, as a dynamic process [1]. It permits to maintain the mechanical bone
strength by preserving the most important minerals’ homeostasis. It consists of a
spatial and temporal coupling of two main phases: (i) old bone resorption and (ii)
new bone formation. This process is controlled by a variety of signaling mechanisms
that orchestrate bone cells functioning. These cells are: (i) osteoblasts, (ii) osteo-
clasts, and (iii) osteocytes. Osteoblasts are mononucleated cells that derive from
mesenchymal stem cells (MSCs), which originate in the bone marrow. These lasts
are responsible of bone formation. Then, osteoclasts are multinucleated cells that
derive from hematopoietic stem cells, which are notably produced in the bone
marrow. These lasts are the only cells able to degrade bone [2, 3]. Eventually,
osteocytes are the cells type that represent the highest amount of bone cells in the
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body (90–95%) [4]. They are the result of the last differentiation of the osteogenic
lineage and have a mechanosensing feature that allow them to feel the mechanical
loading applied on the bone matrix and release various signaling factors that trig-
gers the other bone cells to start their activity. During bone remodeling process,
these cells are interacting with each other and various biochemical and mechanical
factors are orchestrating their functioning [5]. Bone diseases emerge when the
normal process of bone remodeling is interrupted. This result is generally occurring
when the balance of the biochemical factors controlling the process is lost. Indeed,
there are many types of bone diseases. Yet, some of them are more common than
the others. The most prevalent types of bone problems are osteoporosis, Paget’s
disease of bone, and cancer-associated bone loss. Three cancer types are affecting a
large slice of society and induce bone degradation and fracturs: Multiple myeloma,
Breast cancer, and Prostate cancer. Several studies have been interested in analyzing
these bone diseases’ effect and also drugs’ effect on bone remodeling process [5–8]
to predict the bone behavior after getting affected by the disease and determine to
which extent a treatment’s type or specific dose are reducing the effect of the
disease. In the present chapter we are going to provide a description of bone
remodeling and some diseases feature, then to present the different
mechanobiological models dealing with bone diseases and drugs’ effect on bone
remodeling. The chapter is subdivided into three main sequences: (ii) Bone deteri-
oration causes, (ii) Mathematical models of a pathological bone, and (iii)
Mechanobiological models treating bone healing and drugs effect.
2. Bone remodeling
2.1 Generalities
The cell activity leading to bone renewing has been identified by Frost [9] as a
bone multicellular unit (BMU). A mature BMU contains a group of osteoclast and
osteoblast cells, in addition to blood supply associated with the connective tissue.
Knowing that the lifespan of a BMU is higher than the cells one, new osteoclasts and
osteoblasts have to continually adhere to the BMU space in order to maintain its
operation [10]. The bone multicellular units are presented in our skeletal under the
form of discrete foci that could take different shapes, such as the unidirectional, the
branched, and the clustered forms [11]. These foci move forward in all bone com-
partment to assure the renewing of concerned places with a longitudinal advance
rate of 25 μm/day [12].
In order to characterize and discover precisely the movement of bone cells
during the remodeling process, researchers have identified four phases of this
biological phenomenon. First, the activation phase where osteoblasts are excited to
release resorbing cytokines, after receiving the biological signal transmitted by
osteocytes. Osteocytes are a bone cells that are embedded in the bone matrix and
have the ability to sense the mechanical force applied upon the bone. Resorbing
cytokines are responsible of the osteoclasts’ recruitment. The involvement of these
cells engenders the start of resorption phase. During this remodeling step, active
osteoclasts erode the damaged bone matrix by means of ions, acid, and enzymes
[13, 14]. Thereafter, macrophages appear into the gap created and clean the surface
from the remaining bone debris. This step is called the reversal phase and it is
essential to prepare a clean surface for matrix formation. In order to fill in the bone
lacunae, active osteoblasts migrate into the concerned surface and produce the
osteoid, which gets gradually mineralized [15]. The final result of bone remodeling
is, thus, a new, healthy, and stronger bone matrix.
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2.2 Bone cells regulation
As shown above, osteoblast, osteoclast, and osteocytes are predominantly con-
trolling the bone turnover. Thus, it is essential to understand the different steps of
these cells differentiation and how biological factors are regulating their activity.
2.2.1 Regulation of osteoblasts
Osteoblasts are mononucleated cells that derive from mesenchymal stem cells
(MSCs), which originate in the bone marrow. Those cells are multipotent stromal cells
that have the ability to differentiate into a multitude of different cells thanks to their
gene expression program. Among these cells, we can find osteoblasts, fibroblasts,
adipocytes, and chondrocytes [16, 17]. The first step of osteoblastogenesis is regulated
byWingless-int (Wnt), specifically the Wnt10b protein coding gene. In [18], the
authors proved that Wnt plays a key role in the stimulation of MSCs differentiation
into osteo/chondro progenitors and the inhibition of preadipocyte commitment. Sev-
eral other biological factors are involved in MSC differentiation into active osteoblast.
Among which we can cite Runt-related transcriptor factor (Runx2), Osterix (Osc),
Alkaline Phosphatase (ALP), type 1 parathyroid receptor (PTH1R), Osteopontin, and
sialoprotein 2 (BSP II) (Figure 1). The process is described in details in [19].
Based on these information, we can deduct that osteoblastogenesis is a couple of
complex biological interactions involving various factors where a simple alteration
could destroy the whole system. For instance, Runx2, plays an important role in
skeletal development. However, high amount of this transcription factor could
inhibit the osteoblast maturation process and lead consequently to osteopenia
disease [20]. Concurrently, other factors such as bone morphogenetic proteins
(BMPs), transforming growth factor beta (TGFβ), parathyroid hormone (PTH),
and fibroblast growth factor (FGF) have been judged as critical regulator factors of
Runx2 [21]. Aside from Runx2, Wnt/β-catenin and BMPs have also a huge impact
on bone formation and precisely on osteoblastogenesis regulation [22–24].
2.2.2 Regulation of osteoclasts
Osteoclasts are the only cells able to degrade the bone [2, 3]. They derive from
hematopoietic stem cells, which are produced in the bone marrow. By dint of the
macrophage colony stimulating factor (M-CSF), these stem cells are differentiated
into macrophages and osteoclast progenitors. M-CSF is known as one of the main
stimulator factors of osteoclastogenesis as it stimulates preosteoclasts proliferation
and their expression of receptor activator of NFkB (RANK), that represents a key
Figure 1.
Schematic representation of oteoblastogenesis process.
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factor in osteoclasts maturation. Indeed, additionally to its principal function of bone
synthesize, osteoblasts have been reported to regulate osteoclastogenesis through its
secretion of the M-CSF and the receptor activator of NFkB Ligand (RANKL).
According to the literature, RANKL is also secreted by osteocytes [25]. This ligand
expression is stimulated by various types of hormones and factors such as PTH,
prostaglandin E2 (PGE2) and 1.25-dihydroxyvitamin D3 (1:25 OHð Þ2D3). Indeed,
RANKL’s interaction with its receptor RANK is mandatory for osteoclasts’ differenti-
ation, maturation and activation as it induces the recruitment of many hormones
inside the preosteoclasts. RANK/RANKL binding simulates the recruitment of the
tumor necrosis factor receptor associated factor 6 (TRAF6), which triggers a succes-
sion of interactions leading to osteoclastogenesis transcription. During osteoclas-
togenesis the osteoclast progenitors get differentiated into preosteoclasts. Then as a
result of preosteoclasts fusion, mature multinucleated osteoclasts are created, where
the nuclei’s number can variate between four to twenty nuclei [26].
2.2.3 Regulation of osteocytes
Osteocytes represent the highest amount of bone cells in the body (90–95%) [4].
They are the result of the last differentiation of the osteogenic lineage. Indeed, during
bone gap filling, some osteoblasts get trapped into the osteoid and differentiate into
osteocytes [27]. Some authors have distinguished between several stages of
osteocytogenesis. Based on [28], it has been mentioned that the transition from
osteoblasts into osteocytes is governed by seven stages: (i) osteoblast, (iii) osteoblastic
osteocyte (Type 1 preosteocyte), (vi) osteoid osteocyte (Type 2 preosteocyte), (v)
Type 3 preosteocyte, (vi) young osteocyte, and (vii) old osteocyte. Throughout the
transition, a multitude of actions took place. Actually, during all these differential
stages, the cell undergoes many morphological changes to become a cell with den-
dritic extensions [29, 30]. In contrary to MSC to osteoblast transition, the signaling
mechanisms during the process governing osteoblast to osteocyte transition is poorly
understood. However, some authors have recently found some regulating factors
impacting the process such as PTH and insulin-like growth factor type 1 (IGF-1) as,
according to [31], they enhance osteoblast-osteocyte differentiation. The osteocytes
surround the blood vessels in a cylindrical way and are organized in parallel to the
bone surface. They are interconnected between each other by means of their dendritic
extensions that occupy tiny canals called canaliculi. These canaliculi permit the trans-
duction of biochemical signals to other osteocytes and bone cells located in the surface
[32, 33]. Thanks to their characteristics, osteocytes are the best known for their ability
to sense the mechanical loadings and transmit the information to the other bone cells
in such a way the bone remodeling process can start.
2.3 Bone remodeling cycle
Bone remodeling process (Figure 2) as mentioned before is a succession of
events governed by many biochemical factors. In this section, the most important
interactions, actions and reactions are described in summary to show the bone cells
dynamics and their effect on the bone mass changes.
2.3.1 Activation
1.Mechanical loading applied on the skeletal
2.Osteocytes are excited
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3.Osteocytes release biochemical factors stimulating osteoblasts and osteoclasts
(e.g. nitric oxide (NO), sclerostin (SCLR), M-CSF and RANKL) promoting
osteoblast proliferation and osteoclasts differentiation.
4.MSCs release biochemical factor stimulating osteoclastogenesis (e.g. M-CSF
and RANKL)
2.3.2 Formation
1.Differentiation, proliferation, and activity of osteoclasts. The
osteoclastogenesis is mediated by RANK-RANKL binding.
2.Active osteoclasts secrete hydrogen ions and acid phosphatases
3.Mineral phase of the bone matrix is dissolved
4.Active osteoclasts secrete enzymes
5.Organic phase of the bone is resorbed, and embedded biochemical factors are
released (e.g. TGFβ and BMP)




1.Macrophages clean the bone lacunae from bone matrix debris
2.Active osteoblasts adhere to bone lacunae
2.3.4 Formation
1.Active osteoblasts synthetize the collagen to produce the osteoid that gets
gradually mineralized.
Figure 2.
Schematic representation of bone cells main biochemical interactions during bone remodeling process.
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2.At the end osteoblasts differentiate into osteocyte, lining cells or undergo
apoptosis
2.3.5 Termination
1.Signals exciting bone cells decreases in the area
2.BMU recruitment gets smaller
Any interruption of the biological pathways, during remodeling process, can
lead to enormous consequences on the bone cells functioning, which in its turn
leads to very dangerous diseases.
2.4 Bone mechanobiology
The mechanobiology particularity of bone tissue is the base source of its
renewing ability and its capacity to be adapted to external charges. Based on many
experimentations, researchers have found noticeable changes in bone mass, while
variating the external applied charges on the skeleton [34–39]. Thanks to the bone
microarchitecture and its tissue composition, the mechanical loads are transmitted
at the cells’ level as a combination of fluid shear stress and extracellular strain
matrix [40]. Then, thanks to the osteocytes’ mechanosensing mechanisms like ion
channels, integrins, gap junction, and actin cytoskeleton, these cells become able to
release biochemical components (e.g. proteins and cytokines) that regulates osteo-
blasts and osteoclasts’ activity (e.g. increasing their proliferation/differentiation and
inhibiting their apoptosis). For the sake of illustration, we mention the most known
biochemical factors involved: PGE2 [41], NO [42], and SCLR [43]. In addition to
osteocytes, osteoblasts have also been classified as a mechanosensory cell as their
respond to the mechanical signal mediated by the fluid flow by upregulating the
cyclooxygenase-2 (Cox-2) and c-fos and producing intracellular calcium (Ca2+).
3. Bone deterioration causes
3.1 Normal bone diseases
3.1.1 Osteoporosis
Osteoporotic bone is a fragile bone characterized by a low mass (Figure 3) and
deteriorated microstructure. These features are making this bone highly susceptible
to fractures. Osteoporosis is a biochemical problem resulted from both osteoblast
and osteoclast behaviors’ dysregulation that leads to excessive bone resorption. It
affects a large slice of the world’s population, especially women, and it causes
physical debilitation and frequent fracture incidence in patients. Osteoporotic frac-
tures are generally occurring in the spine, hips, femur, and forearm; and they can be
detected in case of a drop in the bone mineral density (BMD) value in the fractured
area [44]. Based on the disease type, scientists have subdivided osteoporosis into
two categories: (i) the primary osteoporosis, which is related to age and hormonal
dysregulation, or unknown causes. This latter case is called idiopathic primary
osteoporosis [45]. Then, (ii) the secondary osteoporosis, which is related to other
diseases appearance (e.g. cancer, hematologic, and gastrointestinal diseases), or to
some treatments use (e.g. Cancer chemotherapeutic drugs, glucocorticoids, and
anticonvulsants [45]).
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3.1.2 Paget’s disease of bone
Paget’s disease of bone is a chronic bone disease, that affect either a single or
multiples parts of the skeletal. The concerned areas are characterized by increased
bone resorption accompanied with increased but disorganized bone formation [46]
(Figure 3). These problems in the bone remodeling process causes deformed and
weak bones. Generally, this disease affect men and the elderly more than women
and young people [47]. The real etiology of this disease is still unknown, however,
40% of patient affected by Paget’s disease have been detected to have a family
history of SQSTM1 gene mutation with a protein regulating osteoclasts called p62
[48]. Advanced Paget’s disease of bone could cause several complication to the
patient, among which, bone pain, bone fractures, and hypercalcemia [49].
3.1.3 Osteogenesis imperfecta
Also known as brittle bone disease, osteogenesis imperfecta is a group of rare
bone diseases characterized by heterogeneous disturbance of the cognitive tissue.
All these diseases are associated with bone mass diminution, increased bone fragil-
ity, bone disfigurement, and bone formation insufficiency [50]. Osteogenesis
imperfecta etiology-associated differ from a disease to another as it depends mainly
on the onsets and intensity of each one. Genetic, phenotypic and functional classi-
fication have been adopted to find out the new causative mutation of osteogenesis
imperfecta onset [51]. The most commonly known osteogenesis imperfecta diseases
are: (i) X-linked hyposphantaemia (XLH), which is characterized by a mutation of
phosphate regulating endopeptidase (PHEX) leading to dysregulate 1,25 OH vita-
min D levels; (ii) Hypoparathyroidism, which is characterized by PTH deficit that
regulate calcium homeostasis; (iii) Hypophosphatasia, which results from mutation
of a responsible gene of encoding ALP called ALPL. The dysregulation of the
enzyme disrupts its function to prompt adequate mineralization at an appropriate
time in bone tissue; and (vi) Osteopetrosis caused by gene mutation code for RANK
and RANKL, leading to an impairment of osteoclasts and thus increased bone mass
with a deterioration of bone quality resulting in atraumatic fractures.
3.2 Metastatic bone diseases
Bone degradation is related to several different factors among which, cancer is
the most discussed issue. Regardless of the cancer type, cancer patients have a
Figure 3.
Difference between normal proximal femur and femur affected by osteoporosis, Paget’s disease, and cancer,
based on medical images.
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higher risk of bone loss than the rest of the population [52]. In fact, bone microen-
vironment enables tumor cells to home, proliferate, and colonize [5]. Thus, gener-
ally, cancer cells migrate form their inherent location to bone microenvironment,
were osteoblasts and osteoclasts secrete important biochemical factors for their
survival [53]. Each cancer type secretes special biochemical factors affecting bone
environment and stimulating their growth. The spread of tumor causes the so-called
bone metastasis disease either if it is a solid tumor (e.g. prostate cancer, breast
cancer) or a liquid tumor (e.g. multiple myeloma). Bone metastasis incidence is
mostly occurring in multiple myeloma patients (95–70%), breast cancer patients
(75–65%), and prostate cancer patients (75–65%) [54].
3.2.1 Multiple myeloma
Multiple myeloma is a blood cancer disease characterized by an abnormal
growth of B-lymphocytes, while differentiating into plasma cells. This cancer is
characterized by renal impairment (creatinine >2 mg/dL), hypercalcemia (calcium
>11 mg/dL) anemia (hemoglobin <10 mg/dL), the infiltration of clonal plasma, and
end organ damage such as lytic lesions in the bone [55, 56]. As mentioned before,
this disease is tightly related to bone degradation. Located in the bone marrow,
multiple myeloma cells are able to interact with bone remodeling cells by means of
adhesion molecules to proliferate and survive [57]. Indeed, multiple myeloma
adhesion incite osteoblastic cells to release interleukin- 6 (IL-6), which has an
essential role in tumor growth and survival [5, 58]. Studies found that multiple
myeloma growth affect both bone formation and bone resorption. On one hand,
they stimulate the differentiation and activity of osteoclasts by secreting RANKL,
the interleukins IL-1, IL-3, IL-6, and the parathyroid hormone-related protein
(PTHrP) that in turn stimulate RANKL expression by osteoblasts. Additionally,
they express syndecan-1, which is a type 1 transmembrane proteoglycan, that binds
OPG [59]. This multiple effects on RANK/RANKL/OPG pathway enhances
osteoclastogenesis and consequently bone resorption. On the other hand, multiple
myeloma cells inhibit the osteoblastogenesis by expressing some biochemical fac-
tors such like Wnt and dickkopf-related protein 1 (DKK-1) [60].
3.2.2 Breast cancer
Breast cancer is a common disease among postmenopausal women. It is charac-
terized by an abnormal growth of breast epithelial cells. Multiple factors are related
to this disease incidence including age, as advancing age increases the risk of getting
breast cancer, gender, as women are the most concerned, personal or family history
of breast cancer, and exogenous hormone use, as some treatments increasing sex
hormones notably estrogen and progesterone [61]. Brest cancer develops because of
DNA damage that could be the result of sex hormones exposure [62]. Epithelial
tumor cells tend as well as the other cancer types, to migrate into the bone micro-
environment and interact with bone cells. Actually, breast cancer tumor cells stim-
ulate RANKL expression and inhibit the OPG one by expressing a multitude of
biochemical factors, among which we note the interukins IL-1, IL-6, IL-8, IL-11, M-
CSF, BMP, DKK-1, PGE2, PTHrP [63]. As a consequence, tumor prevalence in the
bone area induces bone loss.
3.2.3 Prostate cancer
Prostate cancer is a common disease among elderly men, which usually leads to
death as it is the case in the USA [64]. It is characterized by an abnormal growth of
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the prostate basal and luminal epithelial cells [65]. The real etiology of prostate
cancer is still unknown, however, there is some factors related to its incidence. For
instance, age, as advancing age increases the risk of getting prostate cancer, family
history of prostate cancer, and using dietary supplement rich of vitamin E [66].
Similarly to multiple myeloma and breast cancer, prostate tumor cells also adhere to
bone microenvironment and interact with bone cells. It has been reported that
prostate tumor cells secrete PTHrP, Wnt and DKK-1 that regulates osteoblast and
osteoclast behavior once settled in the bone [67, 68]. Thereafter, when prostate
cancer cells adapt to the new environment, they start secreting the prostate- specific
antigen (PSA), that inhibit PTHrP. The high amount of Wnt stimulate osteoblasts
differentiation, and thus RANKL amount increase. When RANKL increases, bone
resorptions is enhanced as result, and the biochemical factors incorporated in the
old bone are released stimulating tumor cells proliferation [7].
4. Mathematical models of a pathological bone
Several studies have been interested in bone diseases’ effect on bone remodeling
process [5]. A large number of the mathematical models, developed in this regard
have been concentrated on the biological aspect related to bone remodeling, so that
they can provide a better understanding of the disease biological effect on the
process.
4.1 Normal bone diseases
Osteoporosis, as it is the most widespread bone disease and the most known
bone problem, it has captured the attention of many authors, especially those
developing bone remodeling mathematical models. Through their mathematical
models, the authors try to schematize as best as possible the osteoporosis disease in
such a way the results could fit the experimental data.
In their study [69], Lemaire and co-authors have investigated the effect of
osteoporosis on the normal biochemical interactions during remodeling process.
They opted for the implementation of three osteoporosis causes: (i) estrogen defi-
ciency, (ii) vitamin D hormone calcitriol (1:25 OHð Þ2D3) deficiency, and (iii) gluco-
corticoid excess. These osteoporosis’ causes have been implemented by changing
some parameters’ value in the principal bone remodeling mathematical model.
According to authors, estrogen deficiency could be represented by decreasing OPG’s
production rate parameter until osteoclast to osteoblast concentration ratio reaches
5 in the steady state. Then, concerning vitamin D deficiency, it could be represented
by increasing the PTH production rate, while glucocorticoid excess could be sche-
matized by decreasing osteoblast progenitors’ differentiation rate. The choices
made by the authors are inspired from the literature: (i) authors have choose to
decrease PTH production, as originally estrogen expression is stimulating OPG
production [70], (ii) PTH effect on bone cells changes with vitamin D3 deficiency,
thus PTH production rate alteration has been based on experimental observations
[71], and (iii) Glucocorticoid induces a decrease in the core binding factor A1
(Cbfa) that is important for osteoblast differentiation, thus, the rate of
preosteoblast differentiation has been reduced to mimic the glucocorticoid excess
effect osteoblastogenesis [72].
Targeting the same objective, Pivonka et al. [73] have studied the RANK-
RANKL-OPG signaling pathway to model osteoporosis disease in postmenopausal
women. In their research study, the catabolic bone disease has been represented
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firstly by decreasing the OPG production value, then by testing a combination of
changed parameter related to the components RANK-RANKL-OPG. The combina-
tion used in the model is based on [74]’s work, where RANK responsiveness and
RANKL production are up-regulated, while OPG production is down-regulated.
These changes enhanced osteoclasts’ response comparably to the osteoblasts’ one.
However, the intensity of bone resorption resulted is different from changing one
parameter to three parameters. Indeed, it has been observed that a change in one
single parameter leads to less sever bone resorption. Overall, the obtained numerical
results were qualitatively consistent with the experimental observation related to
RANK/RANKL/OPG system changes in the case of postmenopausal osteoporosis
(PMO) bone disorder.
Apart from osteoporosis, Paget’s disease has also interested some researchers,
but another time the model developed considering this bone problem have only
treated the biological side of the remodeling process. The work of Komarova et al.
[75] have illustrated the bone cells dynamics in the presence of Paget’s disease. To
proceed, authors have altered the parameters representing the normalized activity
of resorption and formation parameters in addition to the autocrine parameters.
Their model has demonstrated more sensitivity to changes made on the autocrine
parameters’ values. These changes lead to increase bone resorption succeeded by
increased bone formation and represented nearly the same effect of Paget’s disease
of bone. Nevertheless, the real biological process or the particular effects inducing
this type of bone diseases have not been deemed.
4.2 Metastatic bone diseases
Being one of bone metastasis causes, cancer seems to be an important subject to
treat for the clinical interest. As shown before, different types of cancer are causing
bone loss, that could be sometimes escorted by bone formation. These bone changes
are due to the cancer cells growing inside the bone, that represents a rich area
assuring their expansion.
The paper of [76] have treated the problem of cancer’s effect on bone health
independently of the cancer type. Based on a mathematical model composed of
differential equations, authors have calculated bone cells number’s variation, which
depend either from a normal biological process or a disrupted process controlled by
tumor cells growth. According to the tumor growth, the type of bone disorder (i.e.
osteolysis or osteosclerosis) is deducted. Therefore, the types of biochemical
released factors controlling the process are identified (i.e. TGFβ and PTHrP for
osteolysis case/TGFβ and IGF for osteosclerosis case).
In more detailed studies, authors have opted for specific cancer’s type effect on
the remodeling process. For instance, a mathematical model have been described by
Farhat et al. [7] to quantifying bone remodeling changes within the existence of
prostate tumor cells in the bone microenvironment. Based on a large literature
study, the authors managed to detect the main biological factor controlling the
interactions between bone cells and the tumor’s one. In summary, authors have
made the following assumptions:
• Uncommitted osteoblast differentiation into preosteoblasts is governed by
either TGFβ and Wnt.
• Preosteoblasts’ differentiation is controlled not only by TGFβ, but also by the
Wnt. Wnt is playing an activator role in the process, while TGFβ is inhibiting
the differentiation.
10
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• Active osteoclasts apoptosis is variating from a given base rate, then, it follows
TGFβ’s concentration as it performs as a stimulator factor of active osteoclasts’
death.
• Bone formation is controlled by calcium concentration, which plays a
stimulating function, rather than being only relied to active osteoblast
concentration.
Through this article, prostate cancer growth’s impact on the bone remodeling
process has been properly established as each influencing factor has been simply
explained. According to the results, prostate cancer cells existence induces an
increase of RANKL-OPG ratio and bone production. Besides, they found that there
are two osteogenic states over the course of disease.
Multiple myeloma’s influence on bone remodeling has captured more attention
than the other cancers. The research article [6] has provided a model schematizing
multiple myeloma cells’ growth impact on bone cells dynamics. The model has not
clearly shown the biochemical effect of these malignant cells on the normal process.
Although, it has shown their effect on the autocrine and paracrine parameters
described previously in [75]. Authors have suggested a tumor density differential
equation to schematize the metastasis evolution, and they have implemented it
mathematically into the paracrine and autocrine variables to disrupt the normal
oscillation of bone cells during remodeling cycles. This study findings have
completely represented multiple myeloma effect on bone mass evolution. However,
the biological interaction occurring between tumor cells and bone cells have not
been explicitly shown. Thus, the effect of biochemical factors is not clearly
presented.
One year later, a study considered precisely the main biological interactions
occurring during a remodeling process affected by multiple myeloma’s actions. In
the model suggested by Wang et al. [77], multiple myeloma cells behavior have
been modeled by differential equations, which permit to calculate the concentration
of the principal biochemical factors affecting the bone cells. These factors are the
interleukin 6 IL-6, which is secreted by uncommitted osteoblasts promoting multi-
ple myeloma tumor cells’ proliferation, and the very-late antigen 4 (VLA-4), which
mediate Multiple myeloma-Bone marrow-derived mesenchymal stem cells adhesion
and promote IL-6 expression. This antigen effect appears after VLA-4 binding
vascular cell adhesion molecule 1 (VCAM-1) expressed by the uncommitted osteo-
blasts. A further investigation of the problem has been done by [78], where, addi-
tionally to the previous biochemical factors incorporated in the model of [77], they
have added the effect of small leucine-rich proteoglycan (SLRPs). This regulator is
secreted by active osteoblasts. Its main function, in the case on multiple myeloma
tumor cells existence, is to inhibit their proliferation. Through this work, the bio-
chemical mechanism controlling the bone remodeling is clearly described and
properly established by means of the proposed system of differential equations.
5. Mechanobiological mathematical models of a pathological bone
In contrary to strictly biological mathematical models, bone diseases have been
also incorporated into mechanobiological mathematical models, where the
mechanical aspect is taken into consideration. Nevertheless, very few bone diseases
have been discussed through these models. In this chapter, we are going to present
the mechanobiological models treating osteoporosis problem. All the presented
models are based on biological bone remodeling models that represent bone cell
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population through differential Equations [79]. These equations permit to deter-
mine bone cells’ concentration variation over time. The behavior of these cells is
controlled by the most influencing biochemical factors that exist in bone area within
remodeling process.
In the work [80], authors were interested in explaining the experimentally
changes of bone mass in postmenopausal women suffering from osteoporosis,
without neglecting the mechanical influence on the process. Indeed, bone cells
concentration variation over time has been controlled by biochemical factors and
also by the mechanical strains in the extravascular cortical bone matrix. An activa-
tion function Πmechact,OBa (Eq. (1)), representing strains in the extravascular area, was
used to promote preosteoblast proliferation and RANKL production. The mechani-
cal stimulus represented by strain energy density (SED) has a minimum and max-
imum values that correspond respectively to the threshold SED values Ψ bm,min and
Ψ bm,max .Indeed, according to the literature, RANKL/OPG ratio is affected by
hydraulic pressure at the microscopic level [81]. Therefore, RANKL production
function has been formulated as a function of the SED sensed at the bone matrix’s
level. On the other hand, the effect of postmenopausal osteoporosis has been
implemented by considering the effect of mechanical feedback on the progress of
PMO. First, authors have fixed a production rate of PTH that reflect the PMO and
then they variated the maximum proliferation rate of preosteoblasts depending on
the mechanical stimulus’ level. Based on this, various PMO-scenarios have been
established by changing the value of the strength of anabolic strength parameter .
This parameter represents the slope of the activation function. Hence, it determines
the degree of which the SED should be increased to reach the maximum value of the
activation function that allows a maximum proliferation rate to the preostoblasts.
Πmechact,OBa ¼
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Based on the results, bone porosity, calculated based on the bone remodeling
mathematical model, was able to show the severity of PMO evolution over time.
According to the authors, the negligence of the mechanical feedback in the presence
of PMO disease, lead to unbounded bone resorption, which doesn’t reflect the
reality. Thus, every study dealing with biological aspects of bone remodeling should
take into consideration the mechanical aspect as well. With the same perspective,
Pivonka et al. [82], have addressed the geometrical feedback effect upon bone
volume evolution throughout the remodeling process and its capacity of accelerat-
ing osteoporotic porosity evolution. In this study, the osteoporosis origin has not
been mentioned. Yet, its effect has been incorporated by increasing the PTH con-
centration by applying a continuous PTH administration rate of 500 pM/day, as
previously done in [69], which induces an increase of RANKL/OPG’s ratio and
perturbs consequently its homeostatic steady-state.
Several other studies have been interested in osteoporosis effect on bone
remodeling. For instance, [83, 84] are studies where the mechanobiological model
developed by [80] has been modified to include PMO disease effect on bone
remodeling process. RANKL production PRANKl has been modified by adding the
RANKL produced because of the PMO PPMORANKL (Eq. (2)). This term leads to increase
RANKL concentration and enhance preosteoclasts differentiation. The excess
of RANKL production is defined by (Eq. (3)), where PPMO,iniRANKL is PMO-initiating
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formulated as presented in (Eq. (4)). In (Eq. (4)), ξ represents the characteristic
time of the RANKL production decrease, tRANKLPMO determine the shape of Lorentz-



















Furthermore, PMO effect has been mediated by decreasing the anabolic strength
parameter, as previously done in [80].
Recently, PMO problem has been further investigated in the mechanobiological
model described in [85]. PMO effect has been incorporated while taking into con-
sideration the mechanical loading applied on the bone. Indeed, the model mechan-
ical aspect has been similar to the previous discussed work of [80] and PMO effect
was incorporated in a similar way to the work [86], where authors have imposed an
increase in RANKL concentration by including a dosage term that increases RANKL
production. This term is derived from experimental data of ovariectomized rats.
6. Mechanobiological models treating bone healing and drugs effect
Mechanobiological mathematical models of bone remodeling are not only used
to present diseases and mechanical effects on the process. Actually, the main target
of all researchers, by developing these models, is to provide ideas and therapeutic
solutions that could be applied in the real life after a clinical validation. Hence, in
this section, some models considering bone healing and the effect of some bone
diseases’ treatments are discussed.
A mathematical model integrating the biological and mechanical aspects to
describe the process of osteointegration has been described in [87]. The
osteointegration is the direct structural and functional connection between a living
bone and an artificial implant surface [88]. Knowing that many factors are involved
into healing the interface between the non-biological material and bone, a
mechanobiological modeling of the concerned surface is mandatory. In this study,
authors have subdivided the bone healing process into four stages: (i) Blood
clotting, (ii) Cell migration, (iii) Granulation tissue, and finally (iv) bone forma-
tion. The formulated mathematical model, describing the process, took into consid-
eration all the stages of bone-implant healing. Yet, in this chapter, we have only
shed the light on bone formation phase. Researchers have suggested a differential
equation to schematize the osteogenesis stage, that depends on ontogenetic cells’
migration and the osteogenic chemical variables. These two component values have
been calculated based on previous equations describing the former phases.
Concerning the mechanical stimulus, it has been presented through a displacement
matrix.
In another study, authors have developed a mathematical bone remodeling
model gathering the biological factors and the mechanical stimuli’s effect on bone
cells dynamics [89]. This research has been devoted to assess the bone
mechanobiological response and the cellular activity variation over time depending
on specific types of physical activities. Based on the previous works [88, 89], the
bone cells concentrations have been calculated. The mechanical stimuli have been
added to promote the proliferation of the preosteoblast and to regulate RANKL
13
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production. As well as the majority of studies [80, 90, 91], the SED has been used to
schematize the biomechanical stimuli’s influence on cellular dynamics. The SED is
calculated based on the stress and deformation tensors. In this study, these tensors
were decomposed into deviatoric and hydrostatic parts, in order to get both hydro-
static and deviatoric SED quantities. Considering three stimuli in different
remodeling periods, researchers have performed their finite element isotropic
models. Seeking to know the formation performance, cortical and trabecular bone
densities in the diaphysis and epiphysis regions of a proximal femur have been
investigated. The comparison between the three mechanical stimuli (SED,
deviatoric SED, and hydrostatic SED) revealed that: the formation of cortical and
trabecular bone is higher for hydrostatic SED, followed by deviatoric SED, and
finally by the whole SED stimuli. It has been remarked that the thickness of cortical
bone was more significant applying Hydrostatic SED compared with the other
stimulus type, while the trabecular density was higher under deviatoric SED stimu-
lus. This study investigated then many mechanical stimuli and their particularity
and effect on the development of bone density in many regions. Thus, it gave some
insight about bone remodeling especially bone formation phase, which is also a
primordial phase in bone healing process.
Concerning, the investigation of drugs dose effect on bone remodeling, the
traditional mathematical models were not widely used in the literature. Instead,
researchers opted for pharmacokinetic pharmacodynamic (PK/PD) models, which
permit to predict the behavior of the treatment in different compartment of the
body before reaching the blood. The results are then coupled with a traditional bone
remodeling mathematical model. Various studies have been done in this respect,
but which mostly treat the same type of drugs used for bone reparation such as
denosumab. Studding denosumab effect on bone remodeling, this treatment has
been generally included by modifying the function dedicated to calculate RANKL
concentration in such a way the RANKL-binding denosumab is taken into consid-
eration [82, 92]. In the work of [83], the mechanobiological feedback function has
been incorporated to regulate preosteoclasts proliferation as previously done in [80]
and the denosumab effect has been added by adjusting RANKL concentration.
Other studies have been interested in PTH drug’s effect, which is usually used for
postmenopausal women. In the work of [86] for example, authors have created an
equation representing PTH amount in the blood depending on the serum concen-
tration injected. Based on the outcomes, they formulated another function that will
control preosteoblast proliferation, lining cells differentiation, and active osteoclast
apoptosis. Another recent study [85] has been based on [86], have investigated the
same thing, which is PTH effect on bone density. This time, authors have included
PTH into their bone remodeling mathematical model by modifying active osteo-
blasts apoptosis rate multiplying the normal parameter value by the function
representing PTH drug concentration. In contrary to the work of [86], this model
considered the mechanical feedback triggering preosteoblast proliferation. The
term representing this mechanical feedback is the same used in [80].
7. Conclusion
To maintain the multiple functions of a skeletal, this last should be regularly
renewed in such a way the old bone tissue is substituted with a new one. Applying
cyclic mechanical loading on the bone helps to trigger the bone remodeling. Thus,
people doing physical activities generally have stronger bones. On the other hand,
the occurrence of some diseases because of age, hormonal deficiency or bad dietary
habits leads to bone deterioration. The present chapter shed the light on the most
14
BioMechanics and Functional Tissue Engineering
popular bone diseases and the different mechanobiological bone remodeling that
investigate the evolution of these diseases and some drugs effect on the evolution of
bone mass over time. Based on the forgoing reviewed articles, some conclusions
could be extracted:
• Further studies should be elaborated to treat additional bone diseases effect on
bone, especially the prostate and breast cancer.
• Further studies should be elaborated to treat several drugs effect on bone
repairing such as bisphosphonates and estrogen drugs.
• The mechanical aspect is extremely important while investigating the bone
remodeling process as bone is always in touch with the external environment
and the loading effects are not negligible.
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